Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Expenditures: 2015-2023

Historic Capital Expenditures for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Dec 2023 value amounting to $47,000.

  • Rhythm Pharmaceuticals' Capital Expenditures changed negligibly% to -$1,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $46,000, marking a year-over-year decrease of 83.63%. This contributed to the annual value of $47,000 for FY2023, which is 83.27% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Capital Expenditures of $47,000 as of FY2023, which was down 83.27% from $281,000 recorded in FY2022.
  • Rhythm Pharmaceuticals' Capital Expenditures' 5-year high stood at $3.4 million during FY2019, with a 5-year trough of $47,000 in FY2023.
  • In the last 3 years, Rhythm Pharmaceuticals' Capital Expenditures had a median value of $281,000 in 2022 and averaged $254,000.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Capital Expenditures surged by 368.84% in 2019, and later plummeted by 93.68% in 2020.
  • Rhythm Pharmaceuticals' Capital Expenditures (Yearly) stood at $3.4 million in 2019, then slumped by 93.68% to $214,000 in 2020, then spiked by 102.80% to $434,000 in 2021, then tumbled by 35.25% to $281,000 in 2022, then crashed by 83.27% to $47,000 in 2023.